glaxosmithkline update: influenza a (h1n1), page-2

Thanks M, this explains a lot.

Negatives
I was hoping the Melbourne plant was one of the smaller ones, but it looks like it is the biggest.
6m stock - smaller than I expected

Positives
They have filled the last big order (small orders?) so can concentrate on new orders.
China's production will be for internal or LDC's

India is probably the next one to be given a licence. Once again probably for domestic markets or LDC's

Countries are unlikely to break patent.